Jon Asmyr
Plus aucun poste en cours
Fortune : 462 605 $ au 31/03/2024
Profil
Jon Magne Asmyr served as the Chairman of Nordic Nanovector ASA in 2023.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
THOR MEDICAL ASA
1,99% | 31/07/2023 | 4 647 426 ( 1,99% ) | 462 605 $ | 31/03/2024 |
Anciens postes connus de Jon Asmyr
| Sociétés | Poste | Fin |
|---|---|---|
| THOR MEDICAL | Chairman | 28/06/2023 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Nordic Nanovector ASA
 Nordic Nanovector ASA Pharmaceuticals: MajorHealth Technology Nordic Nanovector ASA is a biopharmaceutical company, which engages in the development, marketing, and sale of medical products and equipment for anticancer therapeutics for haematological cancers. The firm offers the Betalutin which is an antibody radionuclide conjugates for the treatment of non-Hodgkin lymphoma. It operates through the following geographical segments: Norway, Switzerland, and the United Kingdom. The company was founded by Roy Hartvig Larsen, Oyvind Sverre Bruland, and Jostein Dahle on July 2, 2009 and is headquartered in Oslo, Norway. | Health Technology |
